Form 4: REGENXBIO CFO Mitchell Chan Granted Stock Options

REGENXBIO's Chief Financial Officer, Mitchell Chan, was granted stock options on January 2, 2025, according to a Form 4 filing.

Summary

• Mitchell Chan, the Chief Financial Officer of REGENXBIO Inc., was granted stock options on January 2, 2025.
• The stock options give Mr. Chan the right to buy 62,547 shares of REGENXBIO's common stock at an exercise price of $7.86 per share.
• 25% of the shares will vest after 12 months of continuous service, with the remainder vesting in equal monthly installments over the following 36 months, starting January 2, 2026.
• Following the transaction, Mr. Chan directly owns 62,547 derivative securities in the form of stock options.
• Patrick J. Christmas, as attorney-in-fact, signed the Form 4 on January 6, 2025, on behalf of Mitchell Chan.
• Mitchell Chan granted power of attorney to Patrick J. Christmas and Curran M. Simpson on September 17, 2024, to handle SEC filings related to REGENXBIO securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options is a standard practice and generally viewed favorably as it aligns management's interests with shareholders. There are no red flags or negative information in the document.

Positives

• The granting of stock options to the CFO aligns his interests with those of the shareholders.
• The vesting schedule incentivizes continued service with the company.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders by incentivizing them to increase the company's stock value.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Amgen, Gilead Sciences, and Biogen also use stock options to incentivize their executives.
• The vesting schedule of 25% after one year and the remainder over the next three years is a typical vesting arrangement.
• The exercise price is usually set at or above the market price on the grant date.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the CFO to improve company performance.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates